Floatz logo

Bortezomib

Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer

Novartis PharmaceuticalsSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer cohort.

Asset / SponsorPhaseRating
Sonidegib
Novartis Pharmaceuticals
Phase 1CC
BKM120
Novartis Pharmaceuticals
Phase 1CC

Same molecule, other indications

Bortezomib is also rated in:

non-small cell lung carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
71 / 100
View asset →
follicular lymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →